menu
    • menu
    [{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Aucta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Aucta Pharmaceuticals \/ Oakrum Pharma, LLC","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Oakrum Pharma, LLC"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Aucta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxcarbazepine","moa":"NaV Channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aucta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Aucta Pharmaceuticals

    Menu

    Aucta Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aucta Pharmaceuticals

                            U.S.A
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAucta is a global brand that creates better products from proven molecules.

                            Lead Product(s) : Lacosamide

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aucta Launches MOTPOLY XR, the First Once-Daily Lacosamide Formulation

                            Details : Motpoly (lacosamide) is an antiepileptic drug that works by blocking sodium channel alpha subunit. It is being evaluated for partial-onset seizures in adults and in pediatric patients.

                            Product Name : Motpoly XR

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 26, 2024

                            Lead Product(s) : Lacosamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Aucta Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aucta Pharmaceuticals

                            U.S.A
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAucta is a global brand that creates better products from proven molecules.

                            Lead Product(s) : Oxcarbazepine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aucta Announced FDA Approval of A Generic Version of Trileptal®(oxcarbazepine) Oral Suspension

                            Details : Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to treat parti...

                            Product Name : Trileptal-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 12, 2022

                            Lead Product(s) : Oxcarbazepine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Aucta Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aucta Pharmaceuticals

                            U.S.A
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAucta is a global brand that creates better products from proven molecules.

                            Lead Product(s) : Formoterol Fumarate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aucta Announces FDA Approval Of A Generic Version Of Perforomist® (formoterol fumarate) Inhalation Solution

                            Details : Formoterol Fumarate is a long-acting bronchodilator used as a long-term treatment to prevent or decrease wheezing and trouble breathing caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchiti...

                            Product Name : Perforomist-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 12, 2022

                            Lead Product(s) : Formoterol Fumarate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Aucta Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aucta Pharmaceuticals

                            U.S.A
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAucta is a global brand that creates better products from proven molecules.

                            Lead Product(s) : Deferasirox

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Oakrum Pharma, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU® Sprinkle (Deferasirox...

                            Details : JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

                            Product Name : Jadenu

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : Deferasirox

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Oakrum Pharma, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Aucta Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth